- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Chelsee Jensen Explains Implementing Biosimilars in Small vs Large Practices
Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Transcript
How does implementing tools for increasing biosimilar use differ between smaller and larger practices?
So, at a smaller practice site where maybe you're operating only in 1 state or maybe you just have a few commercial payers, or even if a majority of your payer mix is government payers, you can probably adopt biosimilars in a full fledge swoop. So, all at once vs our approach, which has been a phased approach of initiating new patients on biosimilars and then choosing a biosimilar at prior authorization renewal. So, if you're in a smaller health system, and you're able to pick a preferred product—because, again, maybe your payer landscape is more standardized—then you can have one set implementation date, have reduced inventory burden, and just improve workflows going forward.
Planetary Health Highlights Global Links Between Climate, Respiratory Well-Being
September 30th 2025At the European Respiratory Society Congress, experts explored the critical connections between climate change, respiratory health, and health equity, highlighting the importance of integrated solutions, local action, and education.
Read More
